Literature DB >> 26520433

A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders.

Howard E Gendelman1, R Lee Mosley2.   

Abstract

Aberrant innate and adaptive immune responses are neurodegenerative disease effectors. Disease is heralded by a generalized, but subtle immune activation orchestrated by the release of extracellular prion-like aggregated and oxidized or otherwise modified proteins. These are responsible for an inflammatory neurotoxic cascade. The perpetrators of such events include effector T cells and activated microglia. What ensues are Alzheimer's and Parkinson's disease, amyotrophic lateral sclerosis and stroke with changed frequencies of effector T cell and reduced numbers or function of regulatory lymphocytes. The control of such immune responses could lead to new therapeutic strategies and the means to effectively combat a composite of diseases that have quite limited therapeutic options.

Entities:  

Keywords:  Adaptive immunity; Alzheimer’s disease; Amyotrophic lateral sclerosis; Effector T cells; Innate immunity; Neurodegenerative diseases; Neurodestruction; Neuroprotection; Parkinson’s disease; Regulatory T cells; Stroke

Mesh:

Year:  2015        PMID: 26520433      PMCID: PMC4662620          DOI: 10.1007/s11481-015-9639-4

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  65 in total

1.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

2.  Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch.

Authors:  Anahit Ghochikyan; Mikayel Mkrtichyan; Irina Petrushina; Nina Movsesyan; Adrine Karapetyan; David H Cribbs; Michael G Agadjanyan
Journal:  Vaccine       Date:  2005-12-05       Impact factor: 3.641

3.  [American Academy of Neurology, Washington, 18-25 April 2015].

Authors:  I Sibon; B de Toffol; J-P Azulay; F Sellal; C Thomas-Antérion; J-M Léger; C Pierrot-Deseilligny
Journal:  Rev Neurol (Paris)       Date:  2015-05-23       Impact factor: 2.607

4.  Letter by Gauberti and Vivien regarding article, "amplification of regulatory T cells using a CD28 superagonist reduces brain damage after ischemic stroke in mice".

Authors:  Maxime Gauberti; Denis Vivien
Journal:  Stroke       Date:  2015-01-13       Impact factor: 7.914

Review 5.  Innate immunity in Alzheimer's disease.

Authors:  Michael T Heneka; Douglas T Golenbock; Eicke Latz
Journal:  Nat Immunol       Date:  2015-03       Impact factor: 25.606

6.  Amplification of regulatory T cells using a CD28 superagonist reduces brain damage after ischemic stroke in mice.

Authors:  Shin-Young Na; Eva Mracsko; Arthur Liesz; Thomas Hünig; Roland Veltkamp
Journal:  Stroke       Date:  2014-11-06       Impact factor: 7.914

Review 7.  Immunosenescence, inflammation and Alzheimer's disease.

Authors:  Adriana Martorana; Matteo Bulati; Silvio Buffa; Mariavaleria Pellicanò; Calogero Caruso; Giuseppina Candore; Giuseppina Colonna-Romano
Journal:  Longev Healthspan       Date:  2012-11-01

Review 8.  Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders.

Authors:  Kristi M Anderson; Katherine E Olson; Katherine A Estes; Ken Flanagan; Howard E Gendelman; R Lee Mosley
Journal:  Transl Neurodegener       Date:  2014-11-13       Impact factor: 8.014

Review 9.  Cerebral amyloid angiopathy: emerging concepts.

Authors:  Masahito Yamada
Journal:  J Stroke       Date:  2015-01-30       Impact factor: 6.967

10.  Partial suppression of M1 microglia by Janus kinase 2 inhibitor does not protect against neurodegeneration in animal models of amyotrophic lateral sclerosis.

Authors:  Satoru Tada; Tatsusada Okuno; Yasumichi Hitoshi; Teruhito Yasui; Josephe Archie Honorat; Kazushiro Takata; Toru Koda; Hiroshi Shimagami; Choong Chi-Jing; Akiko Namba; Tomoyuki Sugimoto; Saburo Sakoda; Hideki Mochizuki; Hitoshi Kikutani; Yuji Nakatsuji
Journal:  J Neuroinflammation       Date:  2014-10-19       Impact factor: 8.322

View more
  22 in total

1.  Low-Dose Maraviroc, an Antiretroviral Drug, Attenuates the Infiltration of T Cells into the Central Nervous System and Protects the Nigrostriatum in Hemiparkinsonian Monkeys.

Authors:  Susanta Mondal; Suresh B Rangasamy; Avik Roy; Sridevi Dasarathy; Jeffrey H Kordower; Kalipada Pahan
Journal:  J Immunol       Date:  2019-05-01       Impact factor: 5.422

2.  Evaluation of regulatory T lymphocytes and IL2Ra and FOXP3 gene expression in peripheral mononuclear cells from patients with amyotrophic lateral sclerosis.

Authors:  Sara Rashid Chehreh Bargh; Abbas Tafakhori; Farimah Masoumi; Farzaneh Rahmani; Mona Ahmadi; Afshin Namdar; Maryam Azimi; Parsova Tavasolian; Sima Habibi; Babak Zamani; Marziyeh Maserrat; Maryam Sadr; Farshid Noorbakhsh; Nima Rezaei
Journal:  Ir J Med Sci       Date:  2018-03-25       Impact factor: 1.568

3.  Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer's disease mice.

Authors:  Tomomi Kiyota; Jatin Machhi; Yaman Lu; Bhagyalaxmi Dyavarshetty; Maryam Nemati; Izumi Yokoyama; R L Mosley; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2018-03-17       Impact factor: 3.478

Review 4.  Dopaminergic Regulation of Innate Immunity: a Review.

Authors:  Monica Pinoli; Franca Marino; Marco Cosentino
Journal:  J Neuroimmune Pharmacol       Date:  2017-06-03       Impact factor: 4.147

5.  Europium-Doped Cerium Oxide Nanoparticles for Microglial Amyloid Beta Clearance and Homeostasis.

Authors:  Jatin Machhi; Pravin Yeapuri; Milica Markovic; Milankumar Patel; Wenhui Yan; Yaman Lu; Jacob D Cohen; Mahmudul Hasan; Mai Mohamed Abdelmoaty; You Zhou; Huangui Xiong; Xinglong Wang; R Lee Mosley; Howard E Gendelman; Bhavesh D Kevadiya
Journal:  ACS Chem Neurosci       Date:  2022-03-21       Impact factor: 5.780

6.  Neutralization of RANTES and Eotaxin Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson Disease.

Authors:  Goutam Chandra; Suresh B Rangasamy; Avik Roy; Jeffrey H Kordower; Kalipada Pahan
Journal:  J Biol Chem       Date:  2016-05-12       Impact factor: 5.157

Review 7.  Adaptive Immunity in Neurodegenerative and Neuropsychological Disorders.

Authors:  R Lee Mosley
Journal:  J Neuroimmune Pharmacol       Date:  2015-10-26       Impact factor: 4.147

8.  Granulocyte-macrophage colony-stimulating factor mRNA and Neuroprotective Immunity in Parkinson's disease.

Authors:  Katherine E Olson; Krista L Namminga; Yaman Lu; Mackenzie J Thurston; Aaron D Schwab; Seymour de Picciotto; Sze-Wah Tse; William Walker; Jared Iacovelli; Clayton Small; Brian T Wipke; R Lee Mosley; Eric Huang; Howard E Gendelman
Journal:  Biomaterials       Date:  2021-03-31       Impact factor: 12.479

9.  Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress.

Authors:  Camille B Carroll; Richard K H Wyse
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

10.  Altered peripheral profile of blood cells in Alzheimer disease: A hospital-based case-control study.

Authors:  Si-Han Chen; Xian-Le Bu; Wang-Sheng Jin; Lin-Lin Shen; Jun Wang; Zheng-Qian Zhuang; Tao Zhang; Fan Zeng; Xiu-Qing Yao; Hua-Dong Zhou; Yan-Jiang Wang
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.